Clonal Hematopoiesis Rates in a Recurrent Venous Thrombosis Population: A Prospective Pilot Study
Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32
DOI: 10.1177/10760296261452879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 21.05.2026. Verfasst von Tamanna Haque und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, The Ohio State Wexner Medical Center, Columbus, OH, USA. Hauptthemen laut MEDLINE: Clonal Hematopoiesis, Venous Thrombosis. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Approximately 50% of venous thromboembolism (VTE) are unprovoked, and 30% recur, leading to significant patient morbidity. Clonal hematopoiesis (CH) are acquired hematopoietic mutations that increase the risk of cardiovascular disease and myeloid neoplasms. CH may be associated with VTE and/or a predictive risk factor for recurrent VTE.
Methods
We conducted the first prospective pilot single-center study for patients with VTE to assess rate of CH, VTE recurrence rate, and clinical outcomes. Subjects with prior VTE underwent blood sample collection and detailed history collection during routine clinic visits. Next generation sequencing of samples was performed with Ion Torrent instrument using a custom Ampliseq 25 gene panel. CH was defined as variant allele frequency (VAF) of 2.0% or greater (CH≥2%). CH with VAF detected between 0.1% to 2.0% were confirmed by random sampling via digital droplet polymerase chain reaction. Statistical analysis on VTE outcomes for CH≥2% and on micro-CH, (defined as CH with VAF of ≥ 0.1%), was performed. Results/Conclusions 167 subjects were enrolled with median follow up of 400 days. Approximately half (45.5%) had history of recurrent VTE and 80% had unprovoked VTE at study enrollment. The CH≥2% rate detected was 13.2% in the study population. There were 9.5 recurrent VTE events per 100 person-years and 40.1 bleeding events per 100 person-years in this study. There were no significant associations between CH and VTE in this pilot study. Larger clinical studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, The Ohio State Wexner Medical Center, Columbus, OH, USA.
- Comprehensive Cancer Center, The Ohio State Wexner Medical Center, Columbus, OH, USA.
- Division of Pathology, The Ohio State Wexner Medical Center, Columbus, OH, USA.
- Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.
- Department of Medicine, University of Ottawaat The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
ORCID-Profile: Tamanna Haque, Rui Li
Zitieren
APA
Haque, T., Lozanski, A., Doong, T. J., Huang, Y., Li, R., Bartosic, A., Landes, K., Lozanski, G., Byrd, J. C., & Wang, T. F. (2026). Clonal Hematopoiesis Rates in a Recurrent Venous Thrombosis Population: A Prospective Pilot Study. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261452879
Vancouver
Haque T, Lozanski A, Doong TJ, Huang Y, Li R, Bartosic A, et al. Clonal Hematopoiesis Rates in a Recurrent Venous Thrombosis Population: A Prospective Pilot Study. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261452879
BibTeX
@article{Haque2026,
author = {Haque, Tamanna and Lozanski, Arletta and Doong, Tzy-Jyye and Huang, Ying and Li, Rui and Bartosic, Abigail and Landes, Kristina and Lozanski, Gerard and Byrd, John C and Wang, Tzu-Fei},
title = {Clonal Hematopoiesis Rates in a Recurrent Venous Thrombosis Population: A Prospective Pilot Study},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
volume = {32},
doi = {10.1177/10760296261452879}
}
EUVIMED